SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Sygnis AG. (10/27/16). "Press Release: Sygnis AG to Receive €1.9 Million Non-dilutive R&D Funding from the Spanish Government". Madrid & Heidelberg.

Region Region Spain (España)
Organisations Organisation Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group Genetrix (ES) (Group)
  Organisation 2 Spain (govt)
Products Product genomic technology
  Product 2 business development (state/region)
Persons Person de la Huerta Martinez, Pilar (Sygnis Pharma 201303– CEO + CFO before Genetrix CEO before Zeltia)
  Person 2 Gabriel, Raimund (MC Services 1999–201101– Founder + CEO)

Public soft loans of €1.2 million and grants of € 0.75 million to fund R&D collaboration of SYGNIS AG with the Spanish National Center for Molecular Biology, San Carlos Hospital and the R&D foundation Juan Dominguez

SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) announced today that the Spanish Ministry of Economy and Competitiveness (MINECO), Department of Research and Development, has granted two soft loans under its prestigious and very competitive RETOS program to fund DNA research projects undertaken by the Company in collaboration with the National Center for Molecular Biology, the San Carlos Hospital and the R&D foundation Juan Dominguez, all collaborators are based in Spain. Through RETOS the Spanish government is financing innovation and scientific research projects of high social and economic impact for small, medium-sized and larger enterprises by providing grants and interest-free or low-interestrate soft loans with long-term durations.

The selection process of business projects for the RETOS program is very strict. The fact that SYGNIS was chosen amongst many candidates, validates the quality and high level of innovation in SYGNIS’ research and development activities.

The soft loans are granted for research and development activities undertaken by SYGNIS and its collaborators relating to SYGNIS’ TruePrime™ and PrimPol™ technologies and the development of a Cell-Free DNA kit. SYGNIS is entitled to receive up to €1.2 million over a period of three years. The loan duration is ten years and interest rate is 0.06%. There is a grace period in the first three years of the loan. Up to €0.75 million will be received by SYGNIS’ collaborators as government grants.

“This non-dilutive and affordable research and development financing of our core technologies by the Spanish government confirms our innovation strategy,” said Pilar de la Huerta, Co-CEO and CFO of SYGNIS AG. “SYGNIS is now part of the exclusive group of Companies that have received financing under the ambitious RETOS program of the Spanish government. We are proud to be announcing this important funding for our research projects. This funding verifies the quality of our projects, the high level of innovation and also the impact potential on society and the economy of SYGNIS’ technologies. This could be exceptional in the case of our Cell-Free DNA kit,” de la Huerta noted.

For further information, please contact:

Pilar de la Huerta Co-CEO/CFO
Phone: +34 91 192 36 50

MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0


SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

SYGNIS AG, Waldhofer Str. 104, 69123 Heidelberg, Germany,, Tel.: + 49-6221- 3540-125, Fax: +49-6221- 3540-127

Record changed: 2017-01-05


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Genetrix (ES) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top